Current Price,can reduce inflammation-induced tissue damage

The realm of peptides is continuously expanding, revealing novel molecules with significant therapeutic potential. Among these, the innate defence regulator peptide (IDR-1018), often referred to simply as IDR-1018 or 1018, has emerged as a compelling subject of research. This synthetic, 12-amino acid peptide, derived from the bovine host-defense peptide (HDP) bactenecin, showcases a remarkable ability to modulate the immune system and combat various infections, making it a promising candidate for a range of biomedical applications.

At its core, IDR-1018 peptide functions as an immunomodulator, actively influencing the host's defense mechanisms. Research indicates that IDR-1018 acts as an immunoregulator, capable of suppressing the pro-inflammatory response by enhancing the production of selective chemokines. This modulation is crucial in managing inflammatory conditions and preventing excessive tissue damage. For instance, in vivo studies with IDR-1018 have demonstrated its capacity to reduce inflammation-induced tissue damage in murine cerebral hypoxia-ischemia. Furthermore, IDR-1018 has been observed to drive macrophage differentiation towards an intermediate M1–M2 state, thereby enhancing anti-inflammatory functions while maintaining essential immune responses.

Beyond its immunomodulatory effects, IDR-1018 exhibits potent antimicrobial and antibiofilm properties. It is recognized as a broad-spectrum antibiofilm peptide, effectively inhibiting biofilm formation and treating pre-existing biofilms. This characteristic is particularly significant in the context of drug-resistant bacterial infections. Studies have shown that IDR-1018 can be used alone or as an adjuvant in combination with conventional antibiotics to treat such infections. This synergy with antibiotics is a key aspect of its therapeutic promise, offering a dual approach to combating challenging microbial threats. The antimicrobial peptide innate defense regulator (IDR)-1018 and its derived peptides have shown promising antimicrobial and antibiofilm activities.

The efficacy of IDR-1018 extends to accelerating wound healing. In a murine model, IDR-1018 demonstrated significantly accelerated wound healing in *S. aureus* infected porcine and non-diabetic murine wounds. This suggests its potential as a topical agent for promoting tissue repair and combating wound infections.

The IDR-1018 peptide is a synthetic, immunomodulatory host defense peptide with a defined sequence of 12 amino acids. Its specific amino acid sequence is VRLIVAVRIWRR-NH2. This relatively small size contributes to its stability and potential for various delivery mechanisms. The IDR-1018 also demonstrates low cytotoxicity, a critical factor for therapeutic peptides.

Research is actively exploring modifications and conjugates of IDR-1018 to further enhance its properties. For example, IDR-1018 can be used to synthesis V-IDR1018 (vancomycin-innate defense regulator conjugate), combining the immunomodulatory effects of IDR-1018 with the potent antibiotic activity of vancomycin. Efforts are also underway to develop cyclic derivatives of IDR-1018 to improve its stability and efficacy. One such development is D1018, a derivative that exhibits higher stability and excellent properties, with the antibacterial activity of all IDR-1018 and its derived peptides lasting for 8–12 hours with high efficiency. Another modified peptide is 1018M, a mutant peptide of innate defense regulator (IDR-)1018 designed for targeted applications.

The development of IDR-1018 has been a subject of patent protection, highlighting its recognized scientific and commercial value. The peptide 1018, also known as innate defence regulator (IDR)-1018, has served as a template polypeptide sequence for further research and development in the field of peptides.

In summary, the IDR-1018 peptide is a versatile molecule with a significant impact on immune modulation, infection control, and wound healing. Its ability to provide protection against bacterial infections, its synergistic potential with conventional antibiotics, and its inherent immunoregulatory functions make it a compelling area of ongoing scientific investigation. As research progresses, the full therapeutic scope of this remarkable innate defence regulator peptide is likely to be further elucidated, paving the way for novel treatment strategies against a range of health challenges.